Insider Trading Alert - FII, RP And CTIC Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, June 27, 2014, 35 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $804.12 to $11,369,294.51.

Highlighted Stocks Traded by Insiders:

Federated Investors (FII) - FREE Research Report

Novak Richard A, who is Principal Accounting Officer at Federated Investors, sold 58 shares at $30.25 on June 27, 2014. Following this transaction, the Principal Accounting Officer owned 39,044 shares meaning that the stake was reduced by 0.15% with the 58-share transaction.

Territ Thomas E, who is Vice President at Federated Investors, sold 127 shares at $30.22 on June 27, 2014. Following this transaction, the Vice President owned 332,574 shares meaning that the stake was reduced by 0.04% with the 127-share transaction.

The shares most recently traded at $30.63, up $0.41, or 1.35% since the insider transaction. Historical insider transactions for Federated Investors go as follows:

  • 4-Week # shares sold: 20,000
  • 12-Week # shares sold: 20,000
  • 24-Week # shares sold: 82,035

The average volume for Federated Investors has been 682,600 shares per day over the past 30 days. Federated Investors has a market cap of $3.2 billion and is part of the financial sector and financial services industry. Shares are up 5.83% year-to-date as of the close of trading on Friday.

Federated Investors, Inc. is a publicly owned asset management holding company. The stock currently has a dividend yield of 3.3%. The company has a P/E ratio of 20.5. Currently, there is 1 analyst who rates Federated Investors a buy, 3 analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FII - FREE

TheStreet Quant Ratings rates Federated Investors as a buy. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year and notable return on equity. We feel these strengths outweigh the fact that the company has had somewhat weak growth in earnings per share. Get the full Federated Investors Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Realpage (RP) - FREE Research Report

Seren Capital, Ltd., who is 10% Owner at Realpage, sold 7,969 shares at $21.92 on June 27, 2014. Following this transaction, the 10% Owner owned 20.1 million shares meaning that the stake was reduced by 0.04% with the 7,969-share transaction.

The shares most recently traded at $22.19, up $0.27, or 1.21% since the insider transaction. Historical insider transactions for Realpage go as follows:

  • 4-Week # shares bought: 50,000
  • 4-Week # shares sold: 19,840
  • 12-Week # shares bought: 50,000
  • 12-Week # shares sold: 97,241
  • 24-Week # shares bought: 50,000
  • 24-Week # shares sold: 105,440

The average volume for Realpage has been 467,800 shares per day over the past 30 days. Realpage has a market cap of $1.7 billion and is part of the technology sector and computer software & services industry. Shares are down 4.36% year-to-date as of the close of trading on Friday.

RealPage, Inc. provides on demand software solutions for the rental housing industry in North America. The company has a P/E ratio of 88.0. Currently, there are 2 analysts who rate Realpage a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on RP - FREE

TheStreet Quant Ratings rates Realpage as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we find that the growth in the company's net income has been quite unimpressive. Get the full Realpage Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Cell Therapeutics (CTIC) - FREE Research Report

Bianco James A, who is President and CEO at Cell Therapeutics, sold 50,000 shares at $2.84 on June 27, 2014. Following this transaction, the President and CEO owned 2.3 million shares meaning that the stake was reduced by 2.13% with the 50,000-share transaction.

The shares most recently traded at $3.01, up $0.17, or 5.65% since the insider transaction. Historical insider transactions for Cell Therapeutics go as follows:

  • 4-Week # shares sold: 77,000
  • 12-Week # shares sold: 99,000
  • 24-Week # shares sold: 1.1 million

The average volume for Cell Therapeutics has been 3.7 million shares per day over the past 30 days. Cell Therapeutics has a market cap of $440.5 million and is part of the health care sector and drugs industry. Shares are up 53.93% year-to-date as of the close of trading on Tuesday.

CTI BioPharma Corp., a biopharmaceutical company, is engaged in the acquisition, development, and commercialization of treatments for cancer.

Exclusive Offer: Get the latest Stock Analysis on CTIC - FREE

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Asia Markets Fall on Latest Tariff Threats From Trump

Asia Markets Fall on Latest Tariff Threats From Trump

Google Invests in JD.com; Comcast-Disney Battle Nears Head -- ICYMI

Google Invests in JD.com; Comcast-Disney Battle Nears Head -- ICYMI

REPLAY: Jim Cramer on Tariff Worries, Oil, Alphabet and Centene

REPLAY: Jim Cramer on Tariff Worries, Oil, Alphabet and Centene

Video: Athens Stock Exchange CEO on What's Next for Greece's Debt Woes

Video: Athens Stock Exchange CEO on What's Next for Greece's Debt Woes

Dow Drops Over 100 Points on Trade War Worries

Dow Drops Over 100 Points on Trade War Worries